Compare Meta Platforms Inc (META) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs TG Therapeutics Inc — how do they compare? Meta Platforms Inc trades at $578.6 (market cap $1.53T), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Meta Platforms Inc is far larger — about 200.3× TG Therapeutics Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| META | TGTX | |
|---|---|---|
Market Cap | $1.53T | $7.64B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $59.06 |
52-Week Low | $525.72 | $26.94 |
Enterprise Value | $1.55T | $7.84B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $599.12, up 0.71% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations at $10.44 EPS versus $6.70 expected, though Q2 2026 missed estimates. Technical indicators show neutral signals with support at $594 and resistance at $608. The company maintains robust revenue growth, reaching $201B in 2025, while investing heavily in AI infrastructure including the recent Muse Spark launch.
Wall Street remains bullish with 79% buy ratings and $761.95 consensus target, representing 27% upside. Key opportunities include AI monetization potential and strong cash flow generation, while risks involve regulatory lawsuits and elevated capital expenditures. The stock presents a compelling growth story but faces execution risks in competitive AI landscape.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
